Back to search
Classical Hodgkin Lymphoma Relapsed
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Classical Hodgkin Lymphoma Relapsed trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Classical Hodgkin Lymphoma Relapsed trials you may qualify forResearchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any…
This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant…
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) o…
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Classical Hodgkin lymphoma (cHL) accounts for 15% of all cases of cancer in children and adolescents and represents the first cause of cancer during adolescence…
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treat…
The goal of this clinical trial is to study the combination of nivolumab and axatilimab in patients with relapsed/refractory classical Hodgkin Lymphoma. This st…
Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the…